Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 8, 2014, Pages 2174-103

  Roberts, Christine ^a   Green, Tina ^b   Hess, Erica ^b   Matys, Katie ^b   Brown, Martha J ^a   Haupt, Richard M ^a   Luxembourg, Alain ^a   Vuocolo, Scott ^a   Saah, Alfred ^a   Antonello, Joseph ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b PPD CGMP Lab   (United States)

Author keywords

Assay; Human papillomavirus; Luminex; Vaccine

Indexed keywords

NEUTRALIZING ANTIBODY; WART VIRUS VACCINE; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; VIROSOME; VIRUS ANTIBODY; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING ASSAY; COMPETITIVE LUMINEX IMMUNOASSAY; CONTROLLED STUDY; CROSS REACTION; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOASSAY; NONHUMAN; PROCESS DEVELOPMENT; QUANTITATIVE ANALYSIS; RHESUS MONKEY; VIRUS LIKE AGENT; WART VIRUS; ANIMAL; BLOOD; DIAGNOSTIC PROCEDURE; DIAGNOSTIC USE; EVALUATION STUDY; HUMAN; IMMUNOLOGY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; PROCEDURES; SENSITIVITY AND SPECIFICITY; VIROLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CLINICAL LABORATORY TECHNIQUES; CROSS REACTIONS; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN G; MACACA MULATTA; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SENSITIVITY AND SPECIFICITY; VIROSOMES;

EID: 84908076244     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.29205     Document Type: Article

References (16)

1. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Vol 100, A Review of Human Carcinogens. Part B: Biological Agents. Lyon, France: International Agency for Research on Cancer; 2011. International Agency for Research on Cancer. 2013.
2. Orozco JJ, Carter JJ, Koutsky LA, Galloway DA. Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers. J Virol 2005; 79:9503-14; PMID:16014913; http://dx.doi.org/10.1128/JVI.79.15.9503-9514.2005
3. Christensen ND, Dillner J, Eklund C, Carter JJ, Wipf GC, Reed CA, Cladel NM, Galloway DA. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 1996; 223:174-84; PMID:8806551; http://dx.doi.org/10.1006/viro.1996.0466
4. Carter JJ, Wipf GC, Madeleine MM, Schwartz SM, Koutsky LA, Galloway DA. Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera. J Virol 2006; 80:4664-72; PMID:16641259; http://dx.doi.org/10.1128/JVI.80.10.4664-4672.2006
5. Dias D, Van Doren J, Schlottmann S, Kelly S, Puchalski D, Ruiz W, Boerckel P, Kessler J, Antonello JM, Green T, et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol 2005; 12:959-69; PMID:16085914
6. Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF, Chirmule N, Esser MT. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003; 10:108-15; PMID:12522048
7. de Villiers E-M, Fauquet C, Broker TR, Bernard H-U, zur Hausen H. Classification of papillomaviruses. Virology 2004; 324:17-27; PMID:15183049; http://dx.doi.org/10.1016/j.virol.2004.03.033
8. Christensen ND, Reed CA, Cladel NM, Hall K, Leiserowitz GS. Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. Virology 1996; 224:477-86; PMID:8874508; http://dx.doi.org/10.1006/viro.1996.0554
9. Christensen ND, Kreider JW, Cladel NM, Patrick SD, Welsh PA. Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11. J Virol 1990; 64:5678-81; PMID:2170694
10. Brown MJ, Seitx H, Towne V, Muller M, Finnefrock AC. Development of neutralizing monoclonal antibodies for oncogenic HPV types 31, 33, 45, 52, and 58. Clin Vaccine Immunol 2014; 21:587-93; PMID:24574536; http://dx.doi.org/10.1128/CVI.00773-13
11. Tan CY, Iglewicz B. Measurement-methods comparisions and linear statistical relationship. Technometrics 1999; 41:192-201; http://dx.doi.org/10.1080/00401706.1999.10485668
12. Kreider JW, Howett MK, Wolfe SA, Bartlett GL, Zaino RJ, Sedlacek T, Mortel R. Morphological transformation in vivo of human uterine cervix with papillomavirus from condylomata acuminata. Nature 1985; 317:639-41; PMID:2997616; http://dx.doi.org/10.1038/317639a0
13. Bryan JT, Jansen KU, Lowe RS, Fife KH, McClowry T, Glass D, Brown DR. Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle IgG concentration. J Med Virol 1997; 53:185-8; PMID:9365880; http://dx.doi.org/10.1002/(SICI)1096-9071(199711)53:3〈185::AIDJMV1〉3.0.CO;2-4
14. Concepcion N, Frasch CE. Evaluation of previously assigned antibody concentrations in pneumococcal polysaccharide reference serum 89SF by the method of cross-standardization. Clin Diagn Lab Immunol 1998; 5:199-204; PMID:9521143
15. Joura E. Efficacy and Immunogenicity of a novel 9-valent HPV L1 virus-like particle vaccine in 16- to 26-year-old women. EUROGIN 2013, November 3-6.Available at http://www.eurogin.com/2013/index.php/abstracts/eurogin-2013-abstracts. 2014.
16. Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, Bosch FX, de Sanjosé S. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer 2012; 7:38; PMID:23273245; http://dx.doi.org/10.1186/1750-9378-7-38